[Immunosuppression and vaccinations].
Immunocompromised subjects have a higher risk of infection. Some infectious risks could be controlled by vaccination, carried out according to normal schedules, in the absence of effective curative treatment. According to the type of immunodeficiency and its severity, certain vaccines may be recommended, others should be avoided and still others may be used with no particular risk. Thus, in immuno-compromised subjects, vaccines consisting of inactivated, inert or dead microorganisms are indicated. In contrast, those consisting of live microbes are not recommended for several reasons: 1) there is a risk that the immunocompromised host will be unable to control infection with the vaccine; 2) there is a risk of an increase in viral replication, particularly in HIV-infected subjects and 3) there is a risk that the response of the immune system will be poor. HIV-infected individuals now account for most of the cases of secondary immuno-deficiency, following the emergence of AIDS in 1980. They are increasing in number, especially in developing countries, where antiretroviral treatment is not widely available. In this context, vaccinations against transmissible childhood viral and bacterial diseases (e.g. measles and polio) with a high prevalence is advisable, with modifications according to the risk of contagion and the degree of immunodeficiency. However, these vaccines do not target opportunist infections, the prognosis of which is poor and against which we have no vaccines. Other vaccines are recommended only for immunocompromised subjects visiting countries with specific epidemiological situations (endemic or epidemic diseases) or if vaccination is required by the country visited.
Débat Zoguéreh
D
D
Faculté des sciences de la santé, Bangui, République centrafricaine.debzog@caramail.com
Ruiz
J M
JM
D016915:AIDS Vaccines / Q000276:immunology; D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology; D000328:Adult; D001428:Bacterial Vaccines / Q000276:immunology; D002648:Child; D015658:HIV Infections / Q000276:immunology; D006679:HIV Seropositivity / Q000276:immunology; D006801:Humans; D007108:Immune Tolerance; D016867:Immunocompromised Host; D007153:Immunologic Deficiency Syndromes; D012307:Risk Factors; D014611:Vaccination; D014765:Viral Vaccines / Q000276:immunology; D014944:World Health Organization
D016915:AIDS Vaccines; D001428:Bacterial Vaccines; D014765:Viral Vaccines